Y-27632 Dihydrochloride: Selective ROCK Inhibitor for Cytoskeletal and Cancer Research

Executive Summary: Y-27632 dihydrochloride is a potent, cell-permeable inhibitor targeting ROCK1 and ROCK2 with sub-micromolar affinity (IC₅₀ ≈ 140 nM for ROCK1; K_i ≈ 300 nM for ROCK2) [ApexBio]. It displays >200-fold selectivity over other kinases, including PKC and MLCK, minimizing off-target effects [ApexBio]. Y-27632 disrupts actomyosin contractility, modulating cellular stress fibers and cytokinesis, and is integral in studies of proliferation, apoptosis, and tissue mechanics (Hinnant et al., 2024). The compound enhances stem cell viability and reduces tumor invasion in both in vitro and in vivo models [BMS345541Hydrochloride]. Proper solubilization and storage protocols are critical for experimental reliability [ApexBio].

Biological Rationale

ROCK1 and ROCK2 are serine/threonine kinases activated by RhoA GTPase. These kinases regulate the phosphorylation of myosin light chain (MLC), stress fiber formation, and focal adhesion assembly. In epithelial and mesenchymal cells, ROCK activity modulates contractility and cell cycle progression. Aberrant ROCK signaling is implicated in cancer cell motility, metastasis, and abnormal tissue repair. Selective inhibition of ROCK1/2 by Y-27632 enables mechanistic dissection of cytoskeletal regulation and contractility-driven processes. For example, in the intestinal epithelium, contractility influences compartment-specific proliferation and apoptosis responses, as shown in recent mouse genetic models (Hinnant et al., 2024). By modulating actomyosin tension, Y-27632 provides a controllable tool for investigating stem cell dynamics, tissue regeneration, and cancer progression.

Mechanism of Action of Y-27632 dihydrochloride

Y-27632 dihydrochloride is a small-molecule inhibitor that competitively binds the ATP-binding pocket of ROCK1 and ROCK2. This binding blocks kinase activity and downstream phosphorylation of MLC and LIMK. The compound's IC₅₀ for ROCK1 is approximately 140 nM, and K_i for ROCK2 is about 300 nM, conferring high potency [ApexBio]. Y-27632 exhibits >200-fold selectivity over kinases such as PKC, cAMP-dependent protein kinase, MLCK, and PAK, reducing nonspecific interference in cellular assays. Functionally, Y-27632 disrupts the assembly of actin stress fibers and impairs Rho-mediated contractile responses. This leads to altered cell shape, suppressed cytokinesis, and changes in cell motility. In stem cell and cancer models, these actions translate to enhanced viability, reduced apoptosis, and decreased invasive potential.

Evidence & Benchmarks

• Y-27632 inhibits ROCK1 with an IC₅₀ of 140 nM and ROCK2 with a K_i of 300 nM, showing >200-fold selectivity over PKC and MLCK (ApexBio Product Page).
• In mouse intestinal epithelium, pharmacological inhibition of contractility via ROCK inhibition modulates proliferation and apoptosis in compartment-specific manners (Hinnant et al., 2024).
• Y-27632 prevents the formation of actin stress fibers in fibroblasts and epithelial cells at concentrations of 10 μM in vitro (Hinnant et al., 2024).
• In cancer models, Y-27632 reduces tumor invasion and metastasis in mouse xenografts (Related Article).
• In stem cell cultures, Y-27632 improves survival and expansion rates, particularly during cell dissociation and passaging (Related Article).

Applications, Limits & Misconceptions

Y-27632 dihydrochloride is used in:

• Dissecting Rho/ROCK signaling pathways in cytoskeletal and cell cycle research.
• Enhancing viability and expansion of human pluripotent stem cells (hPSCs) and primary cells.
• Reducing apoptosis during cell dissociation in tissue engineering workflows.
• Suppressing tumor metastasis and invasion in preclinical cancer studies.
• Modulating contractile responses in epithelial and smooth muscle models.

This article extends the mechanistic insights found in "Y-27632 Dihydrochloride: A Selective ROCK Inhibitor for S..." by integrating recent in vivo genetic evidence and highlighting quantitative selectivity. It also clarifies workflow integration compared to "Y-27632 Dihydrochloride: Selective ROCK Inhibition for St...", emphasizing solubility, storage, and experimental controls.

Common Pitfalls or Misconceptions

• Y-27632 is not effective against non-ROCK kinases such as PKC, PAK, or MLCK at working concentrations; off-target effects are minimal only at much higher doses.
• Long-term storage of aqueous or DMSO solutions can lead to degradation; always prepare fresh aliquots for critical experiments.
• Y-27632 does not reverse established tissue fibrosis or chronic contractile phenotypes in vivo; its action is acute and reversible.
• Not all cell types or tissues respond identically; for instance, intestinal crypts and villi show compartment-specific effects (Hinnant et al., 2024).
• Y-27632 cannot substitute for genetic ablation of ROCK1/2 in mechanistic studies.

Workflow Integration & Parameters

Y-27632 dihydrochloride is supplied as a solid and should be stored desiccated at 4°C, protected from moisture. The compound is soluble at ≥111.2 mg/mL in DMSO, ≥17.57 mg/mL in ethanol, and ≥52.9 mg/mL in water. Solubilization can be enhanced by warming to 37°C or using an ultrasonic bath. Prepare aliquots and store below -20°C for up to several months; avoid repeated freeze-thaw cycles. For in vitro assays, typical working concentrations range from 1 μM to 10 μM. In cell proliferation and cytoskeletal studies, add Y-27632 to culture media immediately before use. In animal models, dosing regimens must be optimized for pharmacokinetic profiles and tissue exposure. For more details, refer to the Y-27632 dihydrochloride A3008 kit.

Conclusion & Outlook

Y-27632 dihydrochloride remains a gold-standard tool for selective ROCK inhibition in cell biology, cancer, and regenerative medicine research. Its high potency and selectivity enable precise modulation of contractility and cytoskeletal organization. Recent advances, including compartment-specific studies of contractility in tissues, further expand its relevance. Researchers should employ validated protocols for solubilization, dosing, and storage to maintain experimental reproducibility. For emerging applications in complex organoid systems and in vivo models, Y-27632 offers a robust platform for dissecting Rho/ROCK signaling dynamics. For more mechanistic depth and translational strategy, see "Y-27632 Dihydrochloride: Redefining Rho/ROCK Pathway Modu...", which contextualizes the compound in cancer-microbiome paradigms.